Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Volition (VNRX) expanded its supply agreement with Fujifilm Vet Systems in Japan to allow development and use of its feline cancer test. The agreement adds the Nu.Q® Vet Feline Test to a relationship that already includes the canine test, launched in Japan in July 2024.
Volition plans to complete product development and launch the feline test on the Immunodiagnostic Systems (IDS) i10® automated analyzer platform. Fujifilm plans a further study with veterinary oncologists in Japan, following a paper reporting that a prototype assay detected lymphoma in cats. The feline product remains in development, rather than a completed commercial launch.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointExpanded Fujifilm supply agreement allows development and use of the Nu.Q® Vet Feline Test in Japan.
- Minor point. Forward-looking: it has not happened yet and may not happen.Feline test launch planned on the IDS i10® automated analyzer platform after product development.
Negative
- None.
Key Figures
- Cats in Japan
- Almost nine million cats
- Population cited in connection with potential use of the feline test
- Lifetime cancer diagnosis rate
- One in five cats
- Cats diagnosed with cancer in their lifetimes
Key Terms
liquid biopsy medical
biomarkers medical
lymphoma medical
epigenetics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expansion extends potential use of Nu.Q® technology to
Volition expects Nu.Q® Vet Feline Test to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer
Junichi Makino, President and Representative Director at Fujifilm Vet Systems, said:
"There are almost nine million cats in
"Since our launch of the Nu.Q® Vet Canine Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, so much so that earlier this year we introduced the automated test to enable a more rapid turnaround and high throughput to meet increasing demand.
"The paper reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats2, the most common cancer in the species3, is incredibly encouraging and we look forward to completing a further study with veterinary oncologists in
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, added:
"Given Fujifilm Vet Systems is a leading provider of diagnostic tests in this large market, the expansion to include feline use presents an exciting revenue opportunity for Volition.
"One in five cats will be diagnosed with cancer in their lifetimes4 and earlier detection can improve outcomes.
"The ownership of cats and dogs has been increasing across the globe, including in emerging economies, with estimates of over a billion cats and dogs worldwide5.
"Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.
"This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.
"We look forward to completing product development and launching the Nu.Q® Vet Feline Test on the Immunodiagnostic Systems (IDS) i10® automated analyzer platform."
- Cat Statistics in
Japan 2026 | 40+ Verified Facts | Cat Statistics 2026 - Canale et al
- Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.
- Cat Cancer Statistics
- Global Pet Statistics
About Fujifilm Vet Systems
Fujifilm Vet Systems is a subsidiary of Fujifilm Holdings Corporation, listed on the Tokyo Stock Exchange under ticker 4901.
Fujifilm Vet Systems provides testing services centered on health checkups to veterinary medical facilities nationwide with relationships throughout the estimated 11,000 veterinary medical facilities in
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Ellen Amonoo, Volition, mediarelations@volition.com
Safe Harbor Statement
Statements contained or referenced herein, including in any associated video or link, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify such statements.
These forward-looking statements relate to, among other topics, Volition's expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases; its expectations regarding future publications; and its success in securing, and the terms of, licensing and/or distribution or other agreements with third parties.
Forward-looking statements are based on current expectations, estimates and projections about Volition's business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: the results of studies testing the efficacy of Volition's tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.
Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.
Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content:https://www.prnewswire.com/news-releases/volition-expands-contract-with-fujifilm-to-include-the-nuq-vet-test-for-cats-302940640.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Volition's expanded Fujifilm agreement cover?
The expanded supply agreement allows development and use of the Nu.Q® Vet Feline Test in Japan. It extends the relationship beyond the Nu.Q® Vet Canine Test, which Fujifilm launched in Japan in July 2024.